NCT07909408
Psilocybin FCR Early-Stage Breast Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Fear of Cancer Recurrence Inventory-Short Form (FCRI-SF)
Timeframe: Baseline, Week 4 Post-Dose Session
Secondary (5)
Change in Clinical Global Impression-Severity (CGI-S) Score
Clinical Global Impression-Improvement (CGI-S) Score
Change in Hospital Anxiety and Depression Scale (HADS) Score
Change in Functional Assessment of Cancer Therapy-Breast (FACT-B) Score
Change in Functional Assessment of Chronic Illness Therapy-Spiritual well-being, 12-items (FACIT-Sp-12) Score
Arms and interventions
Psilocybin 25mgExperimental
1 medication session lasting approximately 8 hours
Psilocybin 5mgActive comparator
1 medication session lasting approximately 8 hours
Drugs: Psilocybin 25 mg, Psilocybin 5 mg
Sites
2 sites in 1 country